Top

Published in:

01-08-2006 | Original Article

Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence

Authors: Con Kelleher, Linda Cardozo, Kathleen Kobashi, Vincent Lucente

Published in: International Urogynecology Journal | Issue 4/2006

Abstract

Patients with mixed urinary incontinence (MUI) are frequently treated with antimuscarinic therapy, despite little data being previously published for this patient group. We present a subgroup analysis of patients with overactive bladder syndrome, assessing the efficacy of once-daily solifenacin succinate in patients with MUI (n=1041) or urge urinary incontinence (UUI; n=1648) only. A greater proportion of patients receiving solifenacin achieved resolution of incontinence in both the MUI and UUI groups (MUI: 5 mg=43%, 10 mg=49%; UUI: 5 mg=55%, 10 mg=54%) compared with patients receiving placebo (MUI 33%, UUI 35%). Baseline to endpoint improvements in all other symptoms were statistically significant vs placebo for both solifenacin doses in both cohorts. The incidence of adverse events was comparable between the MUI and UUI cohorts. This analysis shows that once-daily solifenacin was as effective and well tolerated in patients with MUI as in patients with UUI.

Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87(9):760–766CrossRefPubMed

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37–49CrossRefPubMed

Diokno A, Lee P, Zorn BH, Lenderking WR, Grossman MA, Bull SA, Albrecht D (2001) Factors associated with clinical assessment of overactive bladder and selection of treatment. Clin Ther 23(9):1542–1551CrossRefPubMed

Abrams P, Wein A (2000) Introduction: overactive bladder and its treatments. Urology 55(5A):1–2CrossRefPubMed

Hampel C, Wienhold D, Benken N, Eggersmann C, Thuroff JW (1997) Definition of overactive bladder and epidemiology of urinary incontinence. Urology 50(6A Suppl):4–14. Discussion 15–17CrossRefPubMed

Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. BJOG 104(12):1374–1379CrossRef

Hannestad YS, Rortveit G, Sandvik H, Hunskaar S (2000) A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol 53(11):1150–1157CrossRefPubMed

Wein AJ (2000) Overactive bladder: defining the disease. Am J Manag Care 6(11 Suppl):S559–S5564. Discussion S607–S619PubMed

Rovner E, Wein A (2002) The treatment of overactive bladder in the geriatric patient. Clin Geriatr 10(1):20–25

10.

Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, Kell SH (2003) Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78(6):687–695PubMedCrossRef

11.

Kreder KJ Jr, Brubaker L, Mainprize T (2003) Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int 92(4):418–421CrossRefPubMed

12.

Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93(3):303–310CrossRefPubMed

13.

Cardozo L, Lisec M, Millard R, Trip O, Kuzmin I, Drogendijk T (2004) Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172(5, Part 1 of 2):1919–1924CrossRefPubMed

14.

Gittelman M (2003) Solifenacin succinate 10 mg once daily significantly improves symptoms of overactive bladder. AUA Western 2003 Congress. Abstract 62

15.

Gittelman M (2003) The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study. Int J Gynecol Obstet 83(Suppl 3):94. Abstract TP76CrossRef

16.

Coyne KS, Zhou Z, Thompson C, Versi E (2003) The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 92(7):731–735CrossRefPubMed

Title: Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence
Authors: Con Kelleher
Linda Cardozo
Kathleen Kobashi
Vincent Lucente
Publication date: 01-08-2006
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 4/2006
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-005-0023-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2006

The need for randomised controlled trials in urogynaecology

Female urinary incontinence: a cross-sectional study from a Thai rural area

Prevalence of anal incontinence according to age and gender: a systematic review and meta-regression analysis

Delayed urethral erosion after tension-free vaginal tape

Prevalence of severe pelvic organ prolapse in relation to job description and socioeconomic status: a multicenter cross-sectional study

Factors influencing the long-term success of periurethral collagen therapy in the office